Fig. 1 · Structure
Documents & Downloads
BTX161
CKIα Degrader
BTX161 is a thalidomide analog that functions as an effective degrader of CKIα. This compound promotes the degradation of CKIα in human acute myeloid leukemia (AML) cells, leading to enhanced activation of the DNA damage response (DDR) and p53 while simultaneously stabilizing the p53 antagonist MDM2. BTX161 serves as a valuable tool for studying the role of CKIα in cancer biology and potential therapeutic strategies targeting the DDR pathway.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Degrader |
| CAS Number | 2052301-24-1 |
| Applications | CKIα Degrader |
| Formula | C15H16N2O3 |
| Molecular Weight | 272.30 |
| SMILES | O=C([C@@H](N(CC1=C2C=CC=C1C)C2=O)CCC3)NC3=O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.